Company intelligence / Profile preview
Tianjin Hongri Pharmaceutical
Tianjin, Tianjin, Chinaen.pharm.com.cn ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
The company developed para-toluenesulfonamide, a small molecule inhibitor of carbonic anhydrase, approved in China (Nov 2022) for non-small cell lung cancer. No published multinational clinical results or extensive pipeline available publicly, and clinical data is not detailed in citations.
- Therapeutic areas
- OncologyRare Diseases
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Gongwin Biopharm Holdings Co., Ltd.
Beyond the preview
Go deeper on Tianjin Hongri Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tianjin Hongri Pharmaceutical.